The new frontier of genome engineering with CRISPR-Cas9
The DOI matches its Crossref record; 153 of the 154 references it cites were found in a registry or an index.
Abstract
The advent of facile genome engineering using the bacterial RNA-guided CRISPR-Cas9 system in animals and plants is transforming biology. We review the history of CRISPR (clustered regularly interspaced palindromic repeat) biology from its initial discovery through the elucidation of the CRISPR-Cas9 enzyme mechanism, which has set the stage for remarkable developments using this technology to modify, regulate, or mark genomic loci in a wide variety of cells and organisms from all three domains of life. These results highlight a new era in which genomic manipulation is no longer a bottleneck to experiments, paving the way toward fundamental discoveries in biology, with applications in all branches of biotechnology, as well as strategies for human therapeutics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Repurposing bacterial “CRISPR” systems to facilitate RNA-guided cleavage of complementary DNA has revolutionized the field of gene editing in mammalian cells 1–4.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [3]
In the citing paper
“The CRISPR/Cas9 genome-editing system provides us an unprecedented opportunity to target and modify genomic sequences with high levels of efficacy and specificity [151,152,153,154,155].”
From Cell Immortality: In Vitro Effective Techniques to Achieve and Investigate Its Applications and Challenges (2024) · cites this paper as [152]
In the citing paper
“gene-editing techniques such as CRISPR-Cas9 [11], have led to a “democratization” of molecular biology, with functional and genomic analyses now possible in a wide range of species”
From Back to the Basics: Cnidarians Start to Fire (2017) · cites this paper as [11]
In the citing paper
“This outlook has changed dramatically in the last few years due to the introduction of novel methods that can be directly applied to a wide variety of species.”
From Back to the Basics: Cnidarians Start to Fire (2017) · cites this paper as [11]
In the citing paper
“Cas9:sgRNA recognizes the protospacer-adjacent motif (PAM) sequence and a complementary 20-nucleotide genomic sequence and induces double-strand DNA breaks, which are repaired by error-prone nonhomologous end-joining (NHEJ) or precise homology-directed repair (HDR)2,5.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [2]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Self-citationMultiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210 · cited 5×
“Targeting with multiple sgRNAs—referred to as multiplexing—was also successfully achieved (75, 86).”
InfluentialCRISPR Provides Acquired Resistance Against Viruses in Prokaryotes
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007) · Science · doi:10.1126/science.1138140 · Cited by 5,947 · cited 3×
“provided the first experimental evidence of CRISPRCas–mediated adaptive immunity (45).”
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762 · cited 2×
“Manyoftheseapplicationshavebeendiscussedinre-centreviews( 91 – 93 ).”
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234 · cited 1×
“This approach was also used to identify genes essential for cell viability in cancer and pluripotent stem cells (102).”
Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression
Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013) · Cell · doi:10.1016/j.cell.2013.02.022 · Cited by 5,016 · cited 1×
“coli, whole-genome sequencing showed that there were no detectable off-target effects (127).”
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes
Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., Stern-Ginossar, N., Brandman, O., Whitehead, E. H., Doudna, J. A., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.044 · Cited by 3,696 · cited 1×
“Specifically, fusion of dCas9 to effector domains including VP64 or KRAB allowed stable and efficient transcriptional activation or repression, respectively, in human and yeast cells (129).”
Self-citationWang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
Cited by
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity
Chen, J. S., Ma, E., Harrington, L. B., Da Costa, M., Tian, X., Palefsky, J. M., & Doudna, J. A. (2018) · Science · doi:10.1126/science.aar6245 · Cited by 4,507
Self-citationHigh-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K. (2016) · Nature · doi:10.1038/nature16526 · Cited by 2,673
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
Cheng, Q., Wei, T., Farbiak, L., Johnson, L. T., Dilliard, S. A., & Siegwart, D. J. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0669-6 · Cited by 2,383
CRISPR–Cas9 Structures and Mechanisms
Jiang, F., & Doudna, J. A. (2017) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-062215-010822 · Cited by 2,029
Self-citationHilton, I. B., D'Ippolito, A. M., Vockley, C. M., Thakore, P. I., Crawford, G. E., Reddy, T. E., & Gersbach, C. A. (2015) · Nature Biotechnology · doi:10.1038/nbt.3199 · Cited by 1,885
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,715
Base editing: precision chemistry on the genome and transcriptome of living cells
Rees, H. A., & Liu, D. R. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0059-1 · Cited by 1,675
Engineered CRISPR-Cas9 nucleases with altered PAM specificities
Kleinstiver, B. P., Prew, M. S., Tsai, S. Q., Topkar, V. V., Nguyen, N. T., Zheng, Z., Gonzales, A. P. W., Li, Z., Peterson, R. T., Yeh, J.-R. J., et al. (2015) · Nature · doi:10.1038/nature14592 · Cited by 1,624
Evolved Cas9 variants with broad PAM compatibility and high DNA specificity
Hu, J. H., Miller, S. M., Geurts, M. H., Tang, W., Chen, L., Sun, N., Zeina, C. M., Gao, X., Rees, H. A., Lin, Z., et al. (2018) · Nature · doi:10.1038/nature26155 · Cited by 1,552
The CRISPR tool kit for genome editing and beyond
Adli, M. (2018) · Nature Communications · doi:10.1038/s41467-018-04252-2 · Cited by 1,545
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Dunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410
Hammond, S. M. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.05.001 · Cited by 1,284
A large-scale binding and functional map of human RNA-binding proteins
Van Nostrand, E. L., Freese, P., Pratt, G. A., Wang, X., Wei, X., Xiao, R., Blue, S. M., Chen, J.-Y., Cody, N. A. L., Dominguez, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2077-3 · Cited by 1,317
Off-target Effects in CRISPR/Cas9-mediated Genome Engineering
Zhang, X.-H., Tee, L. Y., Wang, X.-G., Huang, Q.-S., & Yang, S.-H. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.37 · Cited by 1,273
Transcriptional Addiction in Cancer
Bradner, J. E., Hnisz, D., & Young, R. A. (2017) · Cell · doi:10.1016/j.cell.2016.12.013 · Cited by 1,194
“The recent development of genetic and epigenetic editing technologies that can manipulate or repair chromosomal neighborhoods suggests novel therapeutic strategies for such modified cancer genomes (Amabile et al., 2016; Doudna and Charpentier, 2014; Liu et al., 2016b; Wright et al., 2016).”
CRISPR/Cas9 in Genome Editing and Beyond
Wang, H., La Russa, M., & Qi, L. S. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014607 · Cited by 1,110
“The Cas9-mediated gene-editing system has been broadly used in reverse genetics studies to understand the role of specific genes, for disease modeling, and for demonstrating new therapeutic schemes in a number of models of genetic and infectious diseases (9, 10, 94).”
BackgroundMethodGene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
Engineering Quantitative Trait Variation for Crop Improvement by Genome Editing
Rodríguez-Leal, D., Lemmon, Z. H., Man, J., Bartlett, M. E., & Lippman, Z. B. (2017) · Cell · doi:10.1016/j.cell.2017.08.030 · Cited by 1,159
“A powerful approach to create novel allelic variation is through genome editing (Doudna and Charpentier, 2014; Hsu et al., 2014).”
BackgroundEnhanced proofreading governs CRISPR-Cas9 targeting accuracy
Chen, J. S., Dagdas, Y. S., Kleinstiver, B. P., Welch, M. M., Sousa, A. A., Harrington, L. B., Sternberg, S. H., Joung, J. K., Yildiz, A., & Doudna, J. A. (2017) · Nature · doi:10.1038/nature24268 · Cited by 1,168
Self-citationThe bioink: A comprehensive review on bioprintable materials
Hospodiuk, M., Dey, M., Sosnoski, D., & Ozbolat, I. T. (2017) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.12.006 · Cited by 1,118
Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors
Konermann, S., Lotfy, P., Brideau, N. J., Oki, J., Shokhirev, M. N., & Hsu, P. D. (2018) · Cell · doi:10.1016/j.cell.2018.02.033 · Cited by 1,164
“DNAengineering technologies such asCRISPR-Cas9 (Doudna and Charpentier, 2014; Hsu et al., 2014) enable researchers to dissect the function of specific genetic elements or correct disease-causing mutations.”
Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine
Sousa de Almeida, M., Susnik, E., Drasler, B., Taladriz-Blanco, P., Petri-Fink, A., & Rothen-Rutishauser, B. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01127d · Cited by 1,079
DNA Nanotechnology-Enabled Drug Delivery Systems
Hu, Q., Li, H., Wang, L., Gu, H., & Fan, C. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00663 · Cited by 1,118
Richardson, C. D., Ray, G. J., DeWitt, M. A., Curie, G. L., & Corn, J. E. (2016) · Nature Biotechnology · doi:10.1038/nbt.3481 · Cited by 1,098
Breeding crops to feed 10 billion
Hickey, L. T., N. Hafeez, A., Robinson, H., Jackson, S. A., Leal-Bertioli, S. C. M., Tester, M., Gao, C., Godwin, I. D., Hayes, B. J., & Wulff, B. B. H. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0152-9 · Cited by 1,046
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes
Komor, A. C., Badran, A. H., & Liu, D. R. (2017) · Cell · doi:10.1016/j.cell.2016.10.044 · Cited by 1,013
Li, X.-F., & Mitch, W. A. (2018) · Environmental Science & Technology · doi:10.1021/acs.est.7b05440 · Cited by 1,020
On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles
Dilliard, S. A., Cheng, Q., & Siegwart, D. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2109256118 · Cited by 1,018
Applications of CRISPR technologies in research and beyond
Barrangou, R., & Doudna, J. A. (2016) · Nature Biotechnology · doi:10.1038/nbt.3659 · Cited by 1,005
Self-citationCorrection of a pathogenic gene mutation in human embryos
Ma, H., Marti-Gutierrez, N., Park, S.-W., Wu, J., Lee, Y., Suzuki, K., Koski, A., Ji, D., Hayama, T., Ahmed, R., et al. (2017) · Nature · doi:10.1038/nature23305 · Cited by 992
Long, C., Amoasii, L., Mireault, A. A., McAnally, J. R., Li, H., Sanchez-Ortiz, E., Bhattacharyya, S., Shelton, J. M., Bassel-Duby, R., & Olson, E. N. (2016) · Science · doi:10.1126/science.aad5725 · Cited by 937
Non-coding RNA: what is functional and what is junk?
Palazzo, A. F., & Lee, E. S. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00002 · Cited by 901
“This has become more feasible with the advent of CRISPR/Cas9 technology (Doudna and Charpentier, 2014).”
In vitro and ex vivo strategies for intracellular delivery
Stewart, M. P., Sharei, A., Ding, X., Sahay, G., Langer, R., & Jensen, K. F. (2016) · Nature · doi:10.1038/nature19764 · Cited by 885
Yin, H., Song, C.-Q., Dorkin, J. R., Zhu, L. J., Li, Y., Wu, Q., Park, A., Yang, J., Suresh, S., Bizhanova, A., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3471 · Cited by 876
“Cas9:sgRNA recognizes the protospacer-adjacent motif (PAM) sequence and a complementary 20-nucleotide genomic sequence and induces double-strand DNA breaks, which are repaired by error-prone nonhomologous end-joining (NHEJ) or precise homology-directed repair (HDR) 2,5 .”
A century of the phage: past, present and future
Salmond, G. P. C., & Fineran, P. C. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3564 · Cited by 823
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., et al. (2016) · Nature · doi:10.1038/nature20134 · Cited by 864
Genome editing in maize directed by CRISPR–Cas9 ribonucleoprotein complexes
Svitashev, S., Schwartz, C., Lenderts, B., Young, J. K., & Mark Cigan, A. (2016) · Nature Communications · doi:10.1038/ncomms13274 · Cited by 824
“CRISPR–Cas has quickly become the technology of choice for most genome editing applications due to its simplicity, efficiency and versatility 7 .”
Beyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation
Dominguez, A. A., Lim, W. A., & Qi, L. S. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2015.2 · Cited by 832
CIRCLE-Seq: A highly sensitive in vitro screen for genome-wide CRISPR-cas9 nuclease off-targets
Tsai, S. Q., Nguyen, N. T., Malagon-Lopez, J., Topkar, V. V., Aryee, M. J., & Joung, J. K. (2017) · Nature Methods · doi:10.1038/nmeth.4278 · Cited by 814
CRISPR/Cas9 therapeutics: progress and prospects
Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P.-F., & Yu, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01309-7 · Cited by 719
Tools for translation: non-viral materials for therapeutic mRNA delivery
Hajj, K. A., & Whitehead, K. A. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.56 · Cited by 799
Vakulskas, C. A., Dever, D. P., Rettig, G. R., Turk, R., Jacobi, A. M., Collingwood, M. A., Bode, N. M., McNeill, M. S., Yan, S., Camarena, J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0137-0 · Cited by 782
Dissecting Immune Circuits by Linking CRISPR-Pooled Screens with Single-Cell RNA-Seq
Jaitin, D. A., Weiner, A., Yofe, I., Lara-Astiaso, D., Keren-Shaul, H., David, E., Salame, T. M., Tanay, A., van Oudenaarden, A., & Amit, I. (2016) · Cell · doi:10.1016/j.cell.2016.11.039 · Cited by 777
“Current CRISPR/Cas methods are used either for individual gene KOs or for pooled screens (Doudna and Charpentier, 2014; Hsu et al., 2014).”
Whole-organism lineage tracing by combinatorial and cumulative genome editing
McKenna, A., Findlay, G. M., Gagnon, J. A., Horwitz, M. S., Schier, A. F., & Shendure, J. (2016) · Science · doi:10.1126/science.aaf7907 · Cited by 766
Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts
Stewart, M. P., Langer, R., & Jensen, K. F. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00678 · Cited by 747
Svitashev, S., Young, J. K., Schwartz, C., Gao, H., Falco, S. C., & Cigan, A. M. (2015) · Plant Physiology · doi:10.1104/pp.15.00793 · Cited by 733
“931 nucleases (TALENs) advanced genome editing, the recently discovered Cas9-guide RNA (gRNA) system has revolutionized the field (Doudna and Charpentier, 2014; Hsu et al., 2014).”
BackgroundA prudent path forward for genomic engineering and germline gene modification
Baltimore, D., Berg, P., Botchan, M., Carroll, D., Charo, R. A., Church, G., Corn, J. E., Daley, G. Q., Doudna, J. A., Fenner, M., et al. (2015) · Science · doi:10.1126/science.aab1028 · Cited by 733
Self-citationGeneration of knock-in primary human T cells using Cas9 ribonucleoproteins
Schumann, K., Lin, S., Boyer, E., Simeonov, D. R., Subramaniam, M., Gate, R. E., Haliburton, G. E., Ye, C. J., Bluestone, J. A., Doudna, J. A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512503112 · Cited by 702
“T CRISPR/Cas9 system has been used increasingly to edit mammalian germline sequence and cell lines (1, 2).”
MethodSelf-citationAlternatives to Conventional Antibiotics in the Era of Antimicrobial Resistance
Ghosh, C., Sarkar, P., Issa, R., & Haldar, J. (2019) · Trends in Microbiology · doi:10.1016/j.tim.2018.12.010 · Cited by 661
RNA-based therapeutics: an overview and prospectus
Zhu, Y., Zhu, L., Wang, X., & Jin, H. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05075-2 · Cited by 623
“The Cas nuclease then cleaves the dsDNA or an ssRNA at the specific site for efficient genome editing [47].”
BackgroundGenome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells
Kleinstiver, B. P., Tsai, S. Q., Prew, M. S., Nguyen, N. T., Welch, M. M., Lopez, J. M., McCaw, Z. R., Aryee, M. J., & Joung, J. K. (2016) · Nature Biotechnology · doi:10.1038/nbt.3620 · Cited by 670
Paix, A., Folkmann, A., Rasoloson, D., & Seydoux, G. (2015) · Genetics · doi:10.1534/genetics.115.179382 · Cited by 675
“KEYWORDS CRISPR-Cas9; genome editing; homology-directed repair; ribonucleoprotein complexes; C. elegans THE CRISPR-Cas9 system is a bacterial adaptive immunesystem that has been harnessed as a powerful genome editing tool (Doudna and Charpentier 2014).”
MethodAdvances in the delivery of RNA therapeutics: from concept to clinical reality
Kaczmarek, J. C., Kowalski, P. S., & Anderson, D. G. (2017) · Genome Medicine · doi:10.1186/s13073-017-0450-0 · Cited by 656
“So-called CRISPR–Cas systems rely on Watson–Crick base-pairing between a single guide RNA (sgRNA) and a corresponding DNA target site followed by a distinct protospacer-adjacent motif (PAM), a 3–5-nucleotide DNA sequence required for binding of Cas9 and cleavage of the target sequence, in order to introduce a double-s…”
BackgroundThe role of the microbiome in cancer development and therapy
Bhatt, A. P., Redinbo, M. R., & Bultman, S. J. (2017) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21398 · Cited by 653
DeepCRISPR: Optimized CRISPR guide RNA design by deep learning
Chuai, G., Ma, H., Yan, J., Chen, M., Hong, N., Xue, D., Zhou, C., Zhu, C., Chen, K., Duan, B., et al. (2018) · Genome biology · doi:10.1186/s13059-018-1459-4 · Cited by 641
“Such a CRISPR-Cas9 endonuclease system permits genome editing at nucleotide resolution [3, 4], while a major challenge for its effective application is to accurately predict the sgRNA on-target knockout efficacy and off-target (OT) profile beforehand.”
BackgroundThe ALFA-tag is a highly versatile tool for nanobody-based bioscience applications
Götzke, H., Kilisch, M., Martínez-Carranza, M., Sograte-Idrissi, S., Rajavel, A., Schlichthaerle, T., Engels, N., Jungmann, R., Stenmark, P., Opazo, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12301-7 · Cited by 618
Self‐assembled DNA nanoclews for the efficient delivery of CRISPR–Cas9 for genome editing
Sun, W., Ji, W., Hall, J. M., Hu, Q., Wang, C., Beisel, C. L., & Gu, Z. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506030 · Cited by 629
Conformational control of DNA target cleavage by CRISPR–Cas9
Sternberg, S. H., LaFrance, B., Kaplan, M., & Doudna, J. A. (2015) · Nature · doi:10.1038/nature15544 · Cited by 627
Self-citationExosome–Liposome Hybrid Nanoparticles Deliver CRISPR/Cas9 System in MSCs
Lin, Y., Wu, J., Gu, W., Huang, Y., Tong, Z., Huang, L., & Tan, J. (2018) · Advanced Science · doi:10.1002/advs.201700611 · Cited by 625
Structural Basis for Guide RNA Processing and Seed-Dependent DNA Targeting by CRISPR-Cas12a
Swarts, D. C., van der Oost, J., & Jinek, M. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.03.016 · Cited by 608
“RNA-guided nucleases belonging to class 2 CRISPR-Cas systems have emerged as powerful tools for precision genome editing and gene expression control (Charpentier and Marraffini, 2014; Doudna and Charpentier, 2014; Hsu et al., 2014; Mali et al., 2013a).”
MethodIn vitro plant tissue culture: means for production of biological active compounds
Espinosa-Leal, C. A., Puente-Garza, C. A., & García-Lara, S. (2018) · Planta · doi:10.1007/s00425-018-2910-1 · Cited by 582
“The use of this technological approach creates the possibility of producing new plant varieties without the introduction of foreign genes (Doudna and Charpentier 2014; Baltes and Voytas 2015; Nogueira et al.”
BackgroundEfficient delivery of genome-editing proteins using bioreducible lipid nanoparticles
Wang, M., Zuris, J. A., Meng, F., Rees, H., Sun, S., Deng, P., Han, Y., Gao, X., Pouli, D., Wu, Q., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520244113 · Cited by 624
“Our work also demonstrates that the anionic ribonuceloprotein complex formed between Cas9 and single-guide RNA (sgRNA) (2) is able to form a nanocomplex with our bioreducible lipids for efficient genome editing in human cells.”
BackgroundWei, T., Cheng, Q., Min, Y.-L., Olson, E. N., & Siegwart, D. J. (2020) · Nature Communications · doi:10.1038/s41467-020-17029-3 · Cited by 590
Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition
Kleinstiver, B. P., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Topkar, V. V., Zheng, Z., & Joung, J. K. (2015) · Nature Biotechnology · doi:10.1038/nbt.3404 · Cited by 611
Past, present, and future of CRISPR genome editing technologies
Pacesa, M., Pelea, O., & Jinek, M. (2024) · Cell · doi:10.1016/j.cell.2024.01.042 · Cited by 609
Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications
Liu, C., Zhang, L., Liu, H., & Cheng, K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.012 · Cited by 607
Epigenetics and epigenomics in diabetic kidney disease and metabolic memory
Kato, M., & Natarajan, R. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0135-6 · Cited by 600
Delivery technologies for genome editing
Yin, H., Kauffman, K. J., & Anderson, D. G. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.280 · Cited by 597
A Call for Systematic Research on Solute Carriers
César-Razquin, A., Snijder, B., Frappier-Brinton, T., Isserlin, R., Gyimesi, G., Bai, X., Reithmeier, R. A., Hepworth, D., Hediger, M. A., Edwards, A. M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.022 · Cited by 580
Liu, Q., Gao, R., Li, J., Lin, L., Zhao, J., Sun, W., & Tian, C. (2017) · Biotechnology for Biofuels · doi:10.1186/s13068-016-0693-9 · Cited by 576
Direct cytosolic delivery of CRISPR/Cas9-ribonucleoprotein for efficient gene editing
Mout, R., Ray, M., Yesilbag Tonga, G., Lee, Y.-W., Tay, T., Sasaki, K., & Rotello, V. M. (2017) · ACS Nano · doi:10.1021/acsnano.6b07600 · Cited by 579
Genetically modified crops: current status and future prospects
Kumar, K., Gambhir, G., Dass, A., Tripathi, A. K., Singh, A., Jha, A. K., Yadava, P., Choudhary, M., & Rakshit, S. (2020) · Planta · doi:10.1007/s00425-020-03372-8 · Cited by 528
Wang, H.-X., Li, M., Lee, C. M., Chakraborty, S., Kim, H.-W., Bao, G., & Leong, K. W. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00799 · Cited by 560
A Cas9–guide RNA complex preorganized for target DNA recognition
Jiang, F., Zhou, K., Ma, L., Gressel, S., & Doudna, J. A. (2015) · Science · doi:10.1126/science.aab1452 · Cited by 563
Self-citationA dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice
Yang, Y., Wang, L., Bell, P., McMenamin, D., He, Z., White, J., Yu, H., Xu, C., Morizono, H., Musunuru, K., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3469 · Cited by 556
The 60-year evolution of lipid nanoparticles for nucleic acid delivery
Cullis, P. R., & Felgner, P. L. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00977-6 · Cited by 503
Molecular Digital Data Storage Using DNA
Ceze, L., Nivala, J., & Strauss, K. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0125-3 · Cited by 551
DeepPoseKit, a software toolkit for fast and robust animal pose estimation using deep learning
Graving, J. M., Chae, D., Naik, H., Li, L., Koger, B., Costelloe, B. R., & Couzin, I. D. (2019) · eLife · doi:10.7554/elife.47994 · Cited by 547
Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR
Boettcher, M., & McManus, M. T. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.04.028 · Cited by 516
Genetic Management of Fragmented Animal and Plant Populations
Frankham, R., Ballou, J. D., Ralls, K., Eldridge, M., Dudash, M. R., Fenster, C. B., Lacy, R. C., & Sunnucks, P. (2017) · doi:10.1093/oso/9780198783398.001.0001 · Cited by 530
CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors
Wang, D., Zhang, F., & Gao, G. (2020) · Cell · doi:10.1016/j.cell.2020.03.023 · Cited by 527
“…genome editing (Cong et al., 2013; Mali et al., 2013), CRISPR-based technology has rapidly advanced, benefitting greatly from a collective endeavor to characterize, improve, expand, and share the CRISPR-based molecular toolbox (Doudna, 2020; Doudna and Charpentier, 2014; Zhang, 2019).”
Pseudouridylation of tRNA-Derived Fragments Steers Translational Control in Stem Cells
Guzzi, N., Cieśla, M., Ngoc, P. C. T., Lang, S., Arora, S., Dimitriou, M., Pimková, K., Sommarin, M. N. E., Munita, R., Lubas, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.008 · Cited by 518
A Method for the Acute and Rapid Degradation of Endogenous Proteins
Clift, D., McEwan, W. A., Labzin, L. I., Konieczny, V., Mogessie, B., James, L. C., & Schuh, M. (2017) · Cell · doi:10.1016/j.cell.2017.10.033 · Cited by 531
“Traditionally, DNA-modifying methods have been used to knockout proteins on the gene level (Capecchi, 1989), an approach that has had a recent resurgence with the emergence of CRISPR/Cas9 technology (Doudna and Charpentier, 2014).”
MethodCRISPR/Cas system: recent advances and future prospects for genome editing
Manghwar, H., Lindsey, K., Zhang, X., & Jin, S. (2019) · Trends in Plant Science · doi:10.1016/j.tplants.2019.09.006 · Cited by 529
“There are several BE systems that have been used for editing living organisms, including BE3 [32], BE4 [33], Targeted-AID [22], and dCpf1-BE [34].”
BackgroundMethodInfluentialCas9-Guide RNA Directed Genome Editing in Soybean
Li, Z., Liu, Z.-B., Xing, A., Moon, B. P., Koellhoffer, J. P., Huang, L., Ward, R. T., Clifton, E., Falco, S. C., & Cigan, A. M. (2015) · Plant Physiology · doi:10.1104/pp.15.00783 · Cited by 520
“The recognition of PAM by Cas9-gRNA initiates DNA strands separation and RNA-DNA heteroduplex formation that proceeds directionally toward the 59 end of the target sequence (Sternberg et al., 2014; for review, see Doudna and Charpentier, 2014).”
BackgroundScreening out irrelevant cell-based models of disease
Horvath, P., Aulner, N., Bickle, M., Davies, A. M., Nery, E. D., Ebner, D., Montoya, M. C., Östling, P., Pietiäinen, V., Price, L. S., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.175 · Cited by 525
CRISPR Interference Efficiently Induces Specific and Reversible Gene Silencing in Human iPSCs
Mandegar, M. A., Huebsch, N., Frolov, E. B., Shin, E., Truong, A., Olvera, M. P., Chan, A. H., Miyaoka, Y., Holmes, K., Spencer, C. I., et al. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.01.022 · Cited by 525
Defining and improving the genome-wide specificities of CRISPR–Cas9 nucleases
Tsai, S. Q., & Joung, J. K. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.28 · Cited by 510
CRISPR/Cas9-mediated viral interference in plants
Ali, Z., Abulfaraj, A., Idris, A., Ali, S., Tashkandi, M., & Mahfouz, M. M. (2015) · Genome Biology · doi:10.1186/s13059-015-0799-6 · Cited by 500
CRISPR/Cpf1-mediated DNA-free plant genome editing
Kim, H., Kim, S.-T., Ryu, J., Kang, B.-C., Kim, J.-S., & Kim, S.-G. (2017) · Nature Communications · doi:10.1038/ncomms14406 · Cited by 514
“Cpf1, however, differs from Cas9 as follows9,11: (1) Cpf1 recognizes T-rich (such as 50-TTTN-30) PAM sequences; (2) the PAM sequence is located at the 50-end of a target DNA sequence, upstream of a protospacer sequence; (3) Cpf1 is guided by a single crRNA, no trans-acting crRNA is needed9; and (4) Cpf1 is a ribonucle…”
Predicting the mutations generated by repair of Cas9-induced double-strand breaks
Allen, F., Crepaldi, L., Alsinet, C., Strong, A. J., Kleshchevnikov, V., De Angeli, P., Páleníková, P., Khodak, A., Kiselev, V., Kosicki, M., et al. (2019) · Nature Biotechnology · doi:10.1038/nbt.4317 · Cited by 496
Greenwald, E. C., Mehta, S., & Zhang, J. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00333 · Cited by 495
Jia, H., Zhang, Y., Orbović, V., Xu, J., White, F. F., Jones, J. B., & Wang, N. (2017) · Plant Biotechnology Journal · doi:10.1111/pbi.12677 · Cited by 486
“Recent developments in targeted genome editing technologies, however, have facilitated the process to establish genetically modified cultivars that lack transgenes in the final line (Doudna and Charpentier, 2014).”
BackgroundStructure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing
Yin, H., Song, C.-Q., Suresh, S., Wu, Q., Walsh, S., Rhym, L. H., Mintzer, E., Bolukbasi, M. F., Zhu, L. J., Kauffman, K., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.4005 · Cited by 499
Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
Proschak, E., Stark, H., & Merk, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00760 · Cited by 498
CRISPR/Cas9 Platforms for Genome Editing in Plants: Developments and Applications
Ma, X., Zhu, Q., Chen, Y., & Liu, Y.-G. (2016) · Molecular Plant · doi:10.1016/j.molp.2016.04.009 · Cited by 479
Origins and evolution of CRISPR-Cas systems
Koonin, E. V., & Makarova, K. S. (2019) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2018.0087 · Cited by 494
Metadata
- Authors
- Doudna, J. A., & Charpentier, E.
- Affiliations
- Howard Hughes Medical Institute (US)
- Medizinische Hochschule Hannover (DE)
- Corresponding author
- Doudna, Jennifer A.
- Charpentier, Emmanuelle
- Venue
- Science
- Published
- 2014-11-28
- Volume
- 346
- Issue
- 6213
- Pages
- 1258096-1258096
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2050480410
- Semantic Scholar
- e138728065ae7707ff75c3b6a5a52e81856ccf1b
- Cited by
- 7,062
- References
- 154
- Citations by year
- 2026: 560 · 2025: 716 · 2024: 665 · 2023: 580 · 2022: 689 · 2021: 700 · 2020: 653 · 2019: 578 · 2018: 569 · 2017: 545 · 2016: 471 · 2015: 314 · 2014: 3
- FWCI
- 41.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Keywords
- CRISPR/Cas9, genome editing, RNA-guided genome editing, genome modification, genome regulation, biotechnology applications, human therapeutics
- MeSH terms
- Animals, Genetic Engineering, Humans, Genome, Human, Gene Targeting, DNA Cleavage, RNA, Small Untranslated, Clustered Regularly Interspaced Short Palindromic Repeats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.